New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...

It can now also be used as an add-on treatment in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Its original indication is as an add-on maintenance ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids LONDON, UK I October 28, 2024 I ...

(Alliance News) - AstraZeneca PLC on Monday welcomed approval in the European Union of Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis. EGPA is a rare, immune-mediated ...

In January 2024, NS Pharma received orphan drug designation (ODD) from the European Commission (EC) for NS-229, which is being developed to treat eosinophilic granulomatosis with polyangiitis ...

In January 2024, NS Pharma received orphan drug designation (ODD) from the European Commission (EC) for NS-229, which is ...

AstraZeneca’s (LSE: AZN) Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...